Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY-3: Mazdutide versus semaglutide in overweight or obese adults with MAFLD in China
CTR20250920Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide, semaglutide in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, Overweight, sponsored by InnoCare Pharma. Started May 2025; status: active.
02
Drugs
mazdutidesemaglutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesityOverweight
Beyond the preview
Go deeper on CTR20250920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250920.